Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC [Phase 3]

View source ↗

Summary

A global Phase III trial is evaluating Rilvegostomig or Pembrolizumab plus chemotherapy as first-line treatment for metastatic non-squamous non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Non-squamous Non-small Cell Lung Cancer | Phase 3 | Status: RECRUITING